摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-Methyl-2-(piperidin-4-yl)-3,5-dihydroimidazo[4,5-d]pyridazin-4-one trifluoroacetate | 635723-21-6

中文名称
——
中文别名
——
英文名称
5-Methyl-2-(piperidin-4-yl)-3,5-dihydroimidazo[4,5-d]pyridazin-4-one trifluoroacetate
英文别名
5-methyl-2-piperidin-4-yl-1H-imidazo[4,5-d]pyridazin-4-one;2,2,2-trifluoroacetic acid
5-Methyl-2-(piperidin-4-yl)-3,5-dihydroimidazo[4,5-d]pyridazin-4-one trifluoroacetate化学式
CAS
635723-21-6
化学式
C2HF3O2*C11H15N5O
mdl
——
分子量
347.297
InChiKey
IXTXEJMZNANWHD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.76
  • 重原子数:
    24
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    111
  • 氢给体数:
    3
  • 氢受体数:
    9

反应信息

  • 作为产物:
    参考文献:
    名称:
    Condensed imidazole derivatives
    摘要:
    本发明涉及以下公式所代表的化合物,或其盐或水合物 其中, T 1 代表一个含有一个或两个氮原子的4-至12-成员杂环基团,在环中是单环或双环结构,可能具有一个或多个取代基; X代表一个C 1-6 烷基基团,可能具有一个或多个取代基,或类似物; Z 1 和Z 2 各自独立地代表一个氮原子或由公式—CR 2 —所代表的基团; R 1 和R 2 独立地代表氢原子,一个C 1-6 烷基基团,可能具有一个或多个取代基,或一个C 1-6 烷氧基基团,可能具有一个或多个取代基,或类似物。 这些是表现出优异DPPIV抑制活性的新颖化合物。
    公开号:
    US20040116328A1
点击查看最新优质反应信息

文献信息

  • Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
    申请人:CEPHALON FRANCE
    公开号:EP1589016A1
    公开(公告)日:2005-10-26
    The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions of compounds of Formula (A): wherein Ar, Y, R1 and q are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, treatment of attention deficit hyperactivity disorder ("ADHD"), enhancing function in disorders associated with hypofunctionality of the cerebral cortex, including, but not limited to, depression, schizophrenia, fatigue, in particular, fatigue associated with neurologic disease, such as multiple sclerosis, chronic fatigue syndrome, and improvement of cognitive dysfunction.
    本发明涉及化学组合物的制备过程及其用途。特别地,本发明涉及化合物(A)的组合物,其中Ar、Y、R1和q如本文中所定义;以及它们在治疗疾病中的应用,包括治疗嗜睡、促进清醒、治疗帕森病、脑缺血、中风、睡眠呼吸暂停、进食障碍、刺激食欲和体重增加、治疗注意力缺陷多动障碍(“ADHD”)、增强与大脑皮层低功能相关的障碍的功能,包括但不限于抑郁症、精神分裂症、疲劳,尤其是与神经疾病如多发性硬化、慢性疲劳综合征相关的疲劳,以及改善认知功能障碍。
  • Novel condensed imidazole derivatives
    申请人:Yoshikawa Seiji
    公开号:US20060100199A1
    公开(公告)日:2006-05-11
    The present invention is related to compounds represented by the following formula, or salts or hydrates thereof wherein, T 1 represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more substituents; X represents a C 1-6 alkyl group which may have one or more substituents, or such; Z 1 and Z 2 each independently represent a nitrogen atom or a group represented by the formula —CR 2 —; R 1 and R 2 independently represent a hydrogen atom, a C 1-6 alkyl group which may have one or more substituents, or a C 1-6 alkoxy group which may have one or more substituents, or such. These are novel compounds that exhibit an excellent
    本发明涉及以下式子所表示的化合物、盐或合物:其中,T1代表一个含有一个或两个氮原子的4-至12元杂环基团,它是一个单环或双环结构,可能有一个或多个取代基;X代表一个C1-6烷基基团,它可能有一个或多个取代基,或者如此;Z1和Z2各自独立地代表一个氮原子或者由公式—CR2—所表示的基团;R1和R2各自独立地代表一个氢原子,一个C1-6烷基基团,它可能有一个或多个取代基,或者一个C1-6烷氧基基团,它可能有一个或多个取代基,或者如此。这些是新颖的化合物,具有优异的性能。
  • CONDENSED IMIDAZOLE DERIVATIVES
    申请人:Yoshikawa Seiji
    公开号:US20090018331A1
    公开(公告)日:2009-01-15
    The present invention is related to compounds represented by the following formula, or salts or hydrates thereof wherein, T 1 represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more substituents; X represents a C 1-6 alkyl group which may have one or more substituents, or such; Z 1 and Z 2 each independently represent a nitrogen atom or a group represented by the formula —CR 2 —; R 1 and R 2 independently represent a hydrogen atom, a C 1-6 alkyl group which may have one or more substituents, or a C 1-6 alkoxy group which may have one or more substituents, or such. These are novel compounds that exhibit an excellent DPPIV-inhibiting activity.
    本发明涉及下式所示的化合物、盐或合物: 其中, T1表示一个4-到12成员的杂环基团,在环中含有一个或两个氮原子,是单环或双环结构,可以有一个或多个取代基; X表示一个C1-6烷基基团,可以有一个或多个取代基; Z1和Z2各自独立地表示一个氮原子或由公式—CR2—表示的基团; R1和R2各自独立地表示氢原子、一个C1-6烷基基团,可以有一个或多个取代基,或一个C1-6烷氧基基团,可以有一个或多个取代基。 这些是具有出色的DPPIV抑制活性的新型化合物。
  • THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES
    申请人:Lesur Brigitte
    公开号:US20090105241A1
    公开(公告)日:2009-04-23
    The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions of compounds of Formula (A): wherein Ar, Y, R 1 and q are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, treatment of attention deficit hyperactivity disorder (“ADHD”), enhancing function in disorders associated with hypofunctionality of the cerebral cortex, including, but not limited to, depression, schizophrenia, fatigue, in particular, fatigue associated with neurologic disease, such as multiple sclerosis, chronic fatigue syndrome, and improvement of cognitive dysfunction.
    本发明涉及化学组成物、其制备方法和组成物的用途。特别地,本发明涉及式(A)化合物的组成物:其中Ar、Y、R1和q如此定义;以及它们在治疗疾病中的应用,包括治疗嗜睡、促进清醒、治疗帕森病、脑缺血、中风、睡眠呼吸暂停、进食障碍、刺激食欲和增重、治疗注意力缺陷多动障碍(“ADHD”)、增强与大脑皮层功能低下相关的疾病的功能,包括但不限于抑郁症、精神分裂症、疲劳,特别是与神经系统疾病相关的疲劳,如多发性硬化症、慢性疲劳综合征,以及改善认知功能。
  • NOVEL FUSED IMIDAZOLE DERIVATIVE
    申请人:Eisai Co., Ltd.
    公开号:EP1514552A1
    公开(公告)日:2005-03-16
    The present invention is related to compounds represented by the following formula, or salts or hydrates thereof wherein, T1 represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more substituents; X represents a C1-6 alkyl group which may have one or more substituents, or such; Z1 and Z2 each independently represent a nitrogen atom or a group represented by the formula -CR2-; R1 and R2 independently represent a hydrogen atom, a C1-6 alkyl group which may have one or more substituents, or a C1-6 alkoxy group which may have one or more substituents, or such. These are novel compounds that exhibit an excellent DPPIV-inhibiting activity.
    本发明涉及下式所代表的化合物或其盐类或合物 其中 T1 代表环中含有一个或两个氮原子的 4 至 12 元杂环基团,其为单环或双环结构,可具有一个或多个取代基; X 代表可带有一个或多个取代基的 C1-6 烷基,或此类; Z1和Z2各自独立地代表一个氮原子或一个由式-CR2-代表的基团; R1和R2各自独立地代表氢原子、C1-6烷基(可带有一个或多个取代基)或C1-6烷氧基(可带有一个或多个取代基)或此类基团。 这些新型化合物具有优异的 DPPIV 抑制活性。
查看更多

同类化合物

阿拉格列汀 间型霉素环-3',5'-单磷酸酯 西地那非杂质 西地那非-嘧啶酮杂质 苯甲腈,4-(5-甲基-1,3-噁噻戊环-2-基)-(9CI) 苯,[(1-甲基环戊基)硫代]- 苄基-(6-氯-1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 羟基氯地那非 磷酸二氢2-甲氧基-5-[(Z)-2-(3,4,5-三甲氧苯基)乙烯基]苯酯 盐(1:?)1,3,5-萘三磺酸,7-[2-[4-[[5-氯-6-甲基-2-(甲磺酰)-4-嘧啶基]氨基]苯基]二氮烯基]-,钠 甲基-(6-甲基磺酰基-1(2)H-吡唑并[3,4-d]嘧啶-4-基)-胺 甲基(1R,2S,4S)-2,5,7-三羟基-6,11-二羰基-2-(2-羰基丙基)-4-{[2,3,6-三脱氧-4-O-(2,6-二脱氧-α-L-来苏-六吡喃糖基)-3-(二甲氨基)-α-L-来苏-六吡喃糖基]氧代}-1,2,3,4,6,11-六氢四省-1-羧酸酯 环己基-(1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 氯化[4-[(4-氯苯基)氰基甲基]-5-氯-m-苯甲基]铵 氮杂环庚-1-基-[7-氯-4-噻吩-2-基-2-(三氟甲基)-1,5,9-三氮杂双环[4.3.0]壬-2,4,6,8-四烯-8-基]甲酮 昔多芬杂质 异丙基 4-(1-甲基-7-氧代-3-丙基-6,7-二氢-1H-吡唑并[4,3-d]嘧啶-5-基)噻吩-2-基磺酰基氨基甲酸酯 噁庚并[3,4-c]吡啶-3,9-二酮,5-乙基-1,4,5,8-四氢-5-羟基-,(5R)- 吡啶-2-基-[7-吡啶-4-基-吡唑[1,5-a]嘧啶-3-基]甲酮 吡唑并[2,3-a]嘧啶 吡唑并[1,5-a]嘧啶-7-胺 吡唑并[1,5-a]嘧啶-7(1h)-酮 吡唑并[1,5-a]嘧啶-6-醇 吡唑并[1,5-a]嘧啶-6-羧酸乙酯 吡唑并[1,5-a]嘧啶-6-羧酸 吡唑并[1,5-a]嘧啶-5-羧酸,3-氰基-4,7-二氢-7-羰基-,甲基酯 吡唑并[1,5-a]嘧啶-5-羧酸 吡唑并[1,5-a]嘧啶-3-胺盐酸盐(1:1) 吡唑并[1,5-a]嘧啶-3-胺;三氟乙酸 吡唑并[1,5-a]嘧啶-3-羰酰氯 吡唑并[1,5-a]嘧啶-3-羧酸乙酯 吡唑并[1,5-a]嘧啶-3-羧酸 吡唑并[1,5-a]嘧啶-3-磺酰胺 吡唑并[1,5-a]嘧啶-3-甲酰胺 吡唑并[1,5-a]嘧啶-3-甲腈 吡唑并[1,5-a]嘧啶-2-羧酸乙酯 吡唑并[1,5-a]嘧啶-2-羧酸 吡唑并[1,5-a]嘧啶,2-甲基-6-(1-甲基乙基)- 吡唑并[1,5-a]嘧啶,2-溴-5,7-二甲基- 吡唑并[1,5-A]嘧啶-7-羧酸 吡唑并[1,5-A]嘧啶-5-胺 吡唑并[1,5-A]嘧啶-5(4H)-酮 吡唑并[1,5-A]嘧啶-3-甲醛 吡唑[1,5-A]嘧啶-5-羧酸甲酯 吡唑[1,5-A]嘧啶-5,7(4H,6H)-二酮 双氯地那非 卡巴地那非 别嘌醇 别嘌呤醇D2 依鲁替尼杂质37